Acrivon Therapeutics, Inc

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Data from AbbVie and Johnson & Johnson will fine-tune OpenFold3 in a confidentiality-preserving environment, powered by Apheris.

Aiforia and Techcyte announce strategic collaboration to advance AI-powered digital pathology Aiforia Technologies Plc, Press Release, March 21, 2025 at 09:00 a.m. EET Aiforia, a trusted provider of d

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

The artificial intelligence (AI) industry has been on a tear in the past two years, and judging by analyst estimates, it's just the beginning. AI-related sales will continue to soar in the coming years,

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson discussed the growing role of AI in clinical trials. | Fortrea's CTO discusses AI's expanding role in clinical trials,

Abridge, a startup that uses artificial intelligence to build medical documents, said on Monday it raised $250 million in a funding round co-led by Elad Gil and IVP.

The result was Athenic AI, a company that uses AI to run data analytics for enterprises across all of their data sources. Zhao, the founder and CEO, said that Athenic's products are designed to be a central nervous system of an organization's databases that can be used by anyone in the company regardless of their coding or data experience.